This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Davie, A. P. Articles by McMurray, J. J. V. Search for Related Content PubMed PubMed Citation Articles by Davie, A. P. Articles by McMurray, J. J. V. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Heart Failure Related Collections Other heart failure Cardiovascular Pharmacology Other hypertension

(Hypertension. 1999;34:457-460.)
© 1999 American Heart Association, Inc.

Scientific Contributions

Effect of Angiotensin-(1-7) and Bradykinin in Patients With Heart Failure Treated With an ACE Inhibitor

Andrew P. Davie; John J. V. McMurray

From the Medical Research Council Clinical Research Initiative in Heart Failure, University of Glasgow, Glasgow, UK.

Correspondence to Dr Andrew P. Davie, Department of Cardiology, Western Infirmary, Glasgow, G11 6NT, UK. E-mail a.davie{at}bio.gla.ac.uk

Abstract—Angiotensin-(1-7) is a product of angiotensin processing that has been proposed to have vasodepressor effects, both on its own and in combination with bradykinin, which may be pathophysiologically and therapeutically important. Despite this, there has been very little examination of its effects in humans and none in heart failure patients or in other patients treated with ACE inhibitors. We therefore sought to determine the effects of angiotensin-(1-7) in patients with heart failure treated with an ACE inhibitor, as well as any interaction with the effects of bradykinin. A locally active dose of angiotensin-(1-7), alone and in combination with bradykinin, was infused into the nondominant brachial artery while forearm blood flow was measured by venous occlusion plethysmography in 8 patients with heart failure treated with ACE inhibitors. Although bradykinin on its own caused profound vasodilation, there was no effect of angiotensin-(1 to 7) on its own or any effect of angiotensin-(1-7) on the response to bradykinin. We conclude that angiotensin-(1-7) is biologically inactive in the forearm circulation of patients with heart failure treated with an ACE inhibitor. The contrast between these findings and previously reported preclinical findings calls into question the relevance of angiotensin-(1-7) to the hemodynamic effects of ACE inhibitors.

Key Words: angiotensin • bradykinin • angiotensin-converting enzyme inhibitors • heart failure • renin-angiotensin system

This article has been cited by other articles:

				S. Keidar, M. Kaplan, and A. Gamliel-Lazarovich ACE2 of the heart: From angiotensin I to angiotensin (1-7) Cardiovasc Res, February 1, 2007; 73(3): 463 - 469. [Abstract] [Full Text] [PDF]

				J. L. Grobe, A. P. Mecca, H. Mao, and M. J. Katovich Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension Am J Physiol Heart Circ Physiol, June 1, 2006; 290(6): H2417 - H2423. [Abstract] [Full Text] [PDF]

				A. H. Schmaier The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2003; 285(1): R1 - R13. [Abstract] [Full Text] [PDF]

				G. Wiemer, L. W. Dobrucki, F. R. Louka, T. Malinski, and H. Heitsch AVE 0991, a Nonpeptide Mimic of the Effects of Angiotensin-(1-7) on the Endothelium Hypertension, December 1, 2002; 40(6): 847 - 852. [Abstract] [Full Text] [PDF]

				J. McMurray, A. P. Davie, A. E. Loot, A. J.M. Roks, R. H. Henning, W. H. van Gilst, R. A. Tio, A. J.H. Suurmeyer, and F. Boomsma Angiotensin-(1-7) Attenuates the Development of Heart Failure After Myocardial Infarction in Rats * Response Circulation, November 12, 2002; 106 (20): e147 - e147. [Full Text] [PDF]

				S. Sasaki, Y. Higashi, K. Nakagawa, H. Matsuura, G. Kajiyama, and T. Oshima Effects of Angiotensin-(1-7) on Forearm Circulation in Normotensive Subjects and Patients With Essential Hypertension Hypertension, July 1, 2001; 38(1): 90 - 94. [Abstract] [Full Text] [PDF]

				B. Tom, R. de Vries, P. R. Saxena, and A.H. J. Danser Bradykinin Potentiation by Angiotensin-(1-7) and ACE Inhibitors Correlates With ACE C- and N-Domain Blockade Hypertension, July 1, 2001; 38(1): 95 - 99. [Abstract] [Full Text] [PDF]

				P. S. Jhund, A. P. Davie, and J. J. V. McMurray Aspirin inhibits the acute venodilator response to furosemide in patients with chronic heart failure J. Am. Coll. Cardiol., April 1, 2001; 37(5): 1234 - 1238. [Abstract] [Full Text] [PDF]

				P. S. Jhund, N. Dawson, A. P. Davie, N. Sattar, J. Norrie, K. P. J. O'Kane, and J. J. V. McMurray Attenuation of endothelin-1 induced vasoconstriction by 17{beta} estradiol is not sustained during long-term therapy in postmenopausal women with coronary heart disease J. Am. Coll. Cardiol., April 1, 2001; 37(5): 1367 - 1373. [Abstract] [Full Text] [PDF]

				T. Wilsdorf, J. V. Gainer, L. J. Murphey, D. E. Vaughan, and N. J. Brown Angiotensin-(1-7) Does Not Affect Vasodilator or TPA Responses to Bradykinin in Human Forearm Hypertension, April 1, 2001; 37(4): 1136 - 1140. [Abstract] [Full Text] [PDF]